临床新型抗凝药物的研究进展

抗凝药物是一类通过影响凝血过程的不同环节进而抑制血液凝固的药物。目前传统的抗凝药物主要包括维生素K拮抗剂(VKA)、普通肝素(UFH)/低分子肝素(LMWH)。但是上述药物的缺点和不良反应使其在临床应用上受到诸多限制。近年来,针对凝血过程中的关键因子成功研发了多种新型抗凝药物,其中以直接凝血酶抑制剂和Xa因子抑制剂的研发最具有代表性,且多项临床试验已经证实这些药物并不劣于传统抗凝药物。本文对这些新药的临床研究进展进行综述。

Advances of novel anticoagulants

Anticoagulants is a family of drugs aiming at different sites of coagulation system in order to inhibit blood coagulation. Vitamin K antagonist, unfrantionated heparin, and low molecular weight heparin have been used in clinical practice for a long time, but they have also been under-used because of their side-effects. Recently, several novel anticoagulants in development have shown promise, and their efficacy and safety are currently being evaluated in numbers of clinical trials.